9 min read
With Its Latest Prominent Variant, SARS-CoV-2 is Up to Its Old Tricks
By Dr. John Kenney on Mar 1, 2024 3:30:09 PM
Antibody Solutions has been tracing the evolution of SARS-CoV-2 from the earliest days of the pandemic. As part of our program developing antibodies to prevent spike protein cell entry via cleavage at the S1/S2 site by furin, we’ve followed the evolution of the S1/S2 sequence as it emerged from one dominant variant to the next. We’ve observed that the Delta variant was likely the most infectious variant of SARS-CoV-2 to date, and we offered our predictions that subsequent Omicron variants – dominant for most of 2023 – would be “highly transmissible, but with lower disease severity,” a prediction that turned out to be correct, both in broad reports and in studies of small patient groups.
Topics: Insights Antibody Generation COVID-19
Filter by Keyword
- Insights (34)
- Events (16)
- COVID-19 (15)
- SARS-CoV-2 (14)
- News (11)
- Molecular Modeling (9)
- Transgenic Animals (6)
- Antibody Discovery (4)
- Therapeutic Targets (3)
- 25th Anniversary (2)
- Omicron (2)
- Therapeutic Monoclonal Antibodies (2)
- Antibody Generation (1)
- Antibody-Drug Conjugate (ADC) (1)
- Antigen (1)
- CAR-T (1)
- Cell Fusion (1)
- Cell therapy (1)
- Functional Assays (1)
- Harbour (1)
- Hybridoma (1)
- IgG purification (1)
- Immunoassays (1)
- Immunogens (1)
- Lambda Light Chain (1)
- Lambda Mouse (1)
- MAbExpress (1)
- Monoclonal (1)
- OmniRat (1)
- Peptides (1)
- Syngeneic (1)
- Target Analysis (1)
- Transgenic H2L2 Mice (1)
- Women In Bio (1)
- igG (1)
- mRNA (1)